<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Kisqali</title>
    <link rel="shortcut icon" href="images/testlogo.png" type="image/x-icon">
    <link rel="stylesheet" href="css.css">
    <style>
        body {
            background-color: rgba(196, 241, 255, 0.562);
        }
        .container {
            text-align: center;
            margin-left: 100px;
            margin-right:100px;
        }
        p {
            font-size: 22px; /* Adjust the font size as desired */
            font-style: italic;
            text-align: justify;
            text-justify: inter-word;
          }
          table {
         border-spacing: 30px;
          }
    </style>
</head>
<body>
    <center>
        <h1>KISQALI</h1><br>
        <table>
            <tr>
                <td><img src="https://5.imimg.com/data5/SELLER/Default/2022/11/AF/DL/OP/158953150/53697-kisqali-ribociclib-jpg-8a293b8a-d47a-49fb-ad7c-f8c8becc1269-250x250.jpeg" width="300px" height="200px"  alt=""></td>

            </tr>
        </table>
            <div class="container">
                    <p>Kisqali is the brand name for the medication ribociclib. It is a prescription medicine used in combination with other drugs to treat a specific type of breast cancer called hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

                        Ribociclib belongs to a class of drugs known as cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. CDK4/6 is a protein that plays a role in cell division and growth, and by inhibiting its activity, ribociclib helps slow down the growth and division of cancer cells.
                        
                        .</p>
            </div>
    </center>
    
</body>
</html>